Tara Brodo
About Tara Brodo
Tara Brodo is a Senior Director of Pricing & Contracting at Accord BioPharma, with extensive experience in pricing strategies and government programs. She has held significant roles at HUTCHMED and Daiichi Sankyo, Inc., and possesses an MBA from Seton Hall University.
Current Role at Accord BioPharma
Tara Brodo serves as the Senior Director of Pricing & Contracting at Accord BioPharma since 2023. In this role, she is responsible for developing pricing and contracting strategies, particularly for oncology and biosimilar product portfolios. Her position is based in Raleigh, North Carolina, and she operates in a remote capacity. Brodo collaborates with leadership to assess key business drivers, risks, and opportunities to enhance profitability and ensure effective commercial execution.
Previous Experience at HUTCHMED
Before joining Accord BioPharma, Tara Brodo worked at HUTCHMED as the Senior Director of Contracts & Pricing from 2021 to 2023. During her tenure, she focused on pricing strategies and contract negotiations, contributing to the company's objectives in the pharmaceutical sector.
Experience at Daiichi Sankyo, Inc.
Tara Brodo held multiple roles at Daiichi Sankyo, Inc. from 2012 to 2021. She served as Director of Contract Analytics from 2012 to 2015, followed by Director of Contract Operations from 2015 to 2016, and then as Director of Contract Operations and Government Price Reporting from 2016 to 2021. Her work involved managing contract operations and ensuring compliance with government pricing regulations.
Educational Background
Tara Brodo earned her Master of Business Administration (MBA) in Management from Seton Hall University. She also holds a Bachelor of Arts (B.A.) in History from Rutgers University. Her educational background provides a strong foundation for her expertise in pricing and contracting within the pharmaceutical industry.
Expertise in Government Programs and Policy
Tara Brodo is recognized as a government programs and policy expert. She is responsible for keeping her organization informed about legislative changes, including the Inflation Reduction Act, and modeling potential impacts on pricing and contracting strategies. Her expertise is essential for navigating the complexities of government regulations in the pharmaceutical sector.